Sugi Predict

Sugi Predict / Compounds / SCHEMBL438294

SCHEMBL438294

SCHEMBL438294

COC(=O)c1nc(C)cnc1C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.50
▸ S1PR4 O95977 1/20 0.40
▸ GRM5 P41594 2/20 0.38
▸ ATM Q13315 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ KDM4E B2RXH2 7/20 0.36
▸ ALDH1A1 P00352 5/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ HPGD P15428 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ SPR P35270 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30803903 1.00 NPSR1 (0.50) NPSR1S1PR4GRM5ATMMAPK1
SCHEMBL5767143 0.86 NPSR1 (0.58) NPSR1S1PR4GRM5ATMMAPK1
SCHEMBL262307 0.83 GRM5 (0.54) NPSR1S1PR4GRM5L3MBTL1KDM4E
SCHEMBL13242156 0.83 NPSR1 (0.48) NPSR1S1PR4GRM5ATMMAPK1
SCHEMBL2256869 0.83 NPSR1 (0.48) NPSR1ATMMAPK1L3MBTL1KDM4E
SCHEMBL5767151 0.81 NPSR1 (0.47) NPSR1S1PR4GRM5ATMMAPK1
SCHEMBL13242152 0.81 NPSR1 (0.47) NPSR1S1PR4GRM5ATMMAPK1
SCHEMBL1475724 0.81 NPSR1 (0.47) NPSR1S1PR4GRM5ATMMAPK1
SCHEMBL361702 0.81 NPSR1 (0.47) NPSR1S1PR4GRM5ATMMAPK1
SCHEMBL31214137 0.81 NPSR1 (0.47) NPSR1ATMMAPK1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 — — EP disclosed
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses MOMA THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-07-17 — — US disclosed
WO-2024211836-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 — — CN disclosed
CN-111918651-B GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-01-30 — — CN disclosed
US-20220340577-A1 GCN2 INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2022-10-27 — — US disclosed
WO-2019148132-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — WO disclosed
WO-2019148132-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — WO disclosed
US-20190233425-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — US disclosed
US-20190233425-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — US disclosed
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 — — EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 — — US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 — — EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 — — US disclosed
US-20120065205-A1 PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2012-03-15 — — US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065205-A1 PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY5R NPSR1 13/4885S1PR4 364/4885GRM5 25/4885
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLQ, POLB, POLK NPSR1 3684/4885S1PR4 2581/4885GRM5 3951/4885
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLA1, SUB1, CTDSP1 NPSR1 2254/4885S1PR4 2258/4885GRM5 4487/4885
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses POLA1, CTDSP1, SUB1 NPSR1 2680/4885S1PR4 2568/4885GRM5 4767/4885
US-20220340577-A1 GCN2 INHIBITORS AND USES THEREOF EIF2AK4, GCN1, GCGR NPSR1 3835/4885S1PR4 4028/4885GRM5 837/4885
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A NPSR1 2131/4885S1PR4 2172/4885GRM5 2763/4885
US-20190233425-A1 GCN2 INHIBITORS AND USES THEREOF EIF2AK4, GCN1, GCGR NPSR1 3835/4885S1PR4 4028/4885GRM5 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.